Flotillin-2: A new potential predictor for prognosis of breast cancer
Sascha Pust, first author
Overexpression of ErbB2 occurs in up to 30% of human breast cancers. ErbB2 is not down-regulated by ligand-induced mechanisms as many other receptors. In a new study now published in Oncogene (journal impact factor 6.4), Sascha Pust (photo) from Kirsten Sandvig's group at the Institute for Cancer Research and coworkers show that flotillins stabilize ErbB2 at the plasma membrane. Moreover, microarray analysis of biopsies of 194 breast cancer patients indicated that flotillin-2 is a good prognostic marker for breast cancer. Depletion of flotillins leads to internalization and degradation of ErbB2, thereby inhibiting the ErbB2-triggered signaling.
This study was a collaboration between several groups, including three groups (Sandvig, Danielsen, Liestøl) from the Center for Cancer Biomedicine (CCB).
From major journals, first or last author from the Institute for Cancer Research
Lund-Andersen C, Torgunrud A, Kanduri C, Dagenborg VJ, Frøysnes IS, Larsen MM, Davidson B, Larsen SG, Flatmark K(2024) Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer J Transl Med, 22(1), 646 DOI 10.1186/s12967-024-05467-2, PubMed 38982444
Hammer Q, Perica K, Mbofung RM, van Ooijen H, Martin KE, Momayyezi P, Varady E, Pan Y, Jelcic M, Groff B, Abujarour R, Krokeide SZ, Lee T, Williams A, Goodridge JP, Valamehr B, Önfelt B, Sadelain M, Malmberg KJ(2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies Cell Stem Cell(in press) DOI 10.1016/j.stem.2024.06.011, PubMed 38981470
Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B(2024) Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials Mol Oncol(in press) DOI 10.1002/1878-0261.13675, PubMed 38978352
Lê Quý K, Chernigovskaya M, Stensland M, Singh S, Leem J, Revale S, Yadin DA, Nice FL, Povall C, Minns DH, Galson JD, Nyman TA, Snapkow I, Greiff V(2024) Benchmarking and integrating human B-cell receptor genomic and antibody proteomic profiling NPJ Syst Biol Appl, 10(1), 73 DOI 10.1038/s41540-024-00402-z, PubMed 38997321
Lund-Andersen C, Torgunrud A, Kanduri C, Dagenborg VJ, Frøysnes IS, Larsen MM, Davidson B, Larsen SG, Flatmark K(2024) Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer J Transl Med, 22(1), 646 DOI 10.1186/s12967-024-05467-2, PubMed 38982444
Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B(2024) Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials Mol Oncol(in press) DOI 10.1002/1878-0261.13675, PubMed 38978352